🚀 VC round data is live in beta, check it out!
Recbio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Recbio and similar public comparables like Climb Bio, Monopar Therapeutics, Formycon, Akebia Therapeutics and more.
Recbio Overview
About Recbio
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Founded
2021
HQ
Employees
531
Website
Sectors
Financials (LTM)
EV
$425M
Recbio Financials
Recbio reported last 12-month revenue of $2M.
In the same LTM period, Recbio generated had net loss of ($89M).
Revenue (LTM)
Recbio P&L
In the most recent fiscal year, Recbio reported revenue of — and EBITDA of ($68M).
Recbio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($68M) | XXX | XXX | XXX |
| Net Profit | ($89M) | XXX | ($82M) | XXX | XXX | XXX |
| Net Margin | (4796%) | XXX | — | XXX | XXX | XXX |
| Net Debt | — | — | $74M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Recbio Stock Performance
Recbio has current market cap of $384M, and enterprise value of $425M.
Market Cap Evolution
Recbio's stock price is $0.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $425M | $384M | 6.7% | XXX | XXX | XXX | $-0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRecbio Valuation Multiples
Recbio trades at 230.3x EV/Revenue multiple, and (6.3x) EV/EBITDA.
EV / Revenue (LTM)
Recbio Financial Valuation Multiples
As of April 11, 2026, Recbio has market cap of $384M and EV of $425M.
Equity research analysts estimate Recbio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Recbio has a P/E ratio of (4.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $384M | XXX | $384M | XXX | XXX | XXX |
| EV (current) | $425M | XXX | $425M | XXX | XXX | XXX |
| EV/Revenue | 230.3x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (6.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (5.2x) | XXX | XXX | XXX |
| P/E | (4.3x) | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Recbio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Recbio Margins & Growth Rates
Recbio's revenue in the last fiscal year grew by —.
Recbio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Recbio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (7%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Recbio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Climb Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Monopar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Formycon | XXX | XXX | XXX | XXX | XXX | XXX |
| Akebia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Benitec Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Recbio M&A Activity
Recbio acquired XXX companies to date.
Last acquisition by Recbio was on XXXXXXXX, XXXXX. Recbio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Recbio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRecbio Investment Activity
Recbio invested in XXX companies to date.
Recbio made its latest investment on XXXXXXXX, XXXXX. Recbio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Recbio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Recbio
| When was Recbio founded? | Recbio was founded in 2021. |
| Where is Recbio headquartered? | Recbio is headquartered in China. |
| How many employees does Recbio have? | As of today, Recbio has over 531 employees. |
| Is Recbio publicly listed? | Yes, Recbio is a public company listed on HKEX. |
| What is the stock symbol of Recbio? | Recbio trades under 02179 ticker. |
| When did Recbio go public? | Recbio went public in 2022. |
| Who are competitors of Recbio? | Recbio main competitors are Climb Bio, Monopar Therapeutics, Formycon, Akebia Therapeutics. |
| What is the current market cap of Recbio? | Recbio's current market cap is $384M. |
| What is the current revenue of Recbio? | Recbio's last 12 months revenue is $2M. |
| What is the current EV/Revenue multiple of Recbio? | Current revenue multiple of Recbio is 230.3x. |
| Is Recbio profitable? | No, Recbio is not profitable. |
| What is the current net income of Recbio? | Recbio's last 12 months net income is ($89M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.